Combined Pharmacotherapy for Cannabis Dependency (D-LUCS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to see if Lofexidine in combination with Marinol is superior to placebo in achieving abstinence, reducing cannabis use and reducing withdrawal in cannabis-dependent patients seeking treatment for their marijuana use.
| Condition | Intervention | Phase |
|---|---|---|
|
Cannabis Dependence Marijuana Dependence |
Drug: Lofexidine and Dronabinol Drug: Placebo |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Randomized, Double-Blind, Placebo-Controlled Study of Lofexidine and Dronabinol for the Treatment of Marijuana Dependence |
- Reduction in self reported days of marijuana use as measured by the Time-line Followback. [ Time Frame: reported daily for 12 weeks/ or study participation ] [ Designated as safety issue: No ]
- Marijuana withdrawal as measured by the MWC-10 item [ Time Frame: reported 2x/week for 12 weeks/ or study participation ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 180 |
| Study Start Date: | January 2010 |
| Estimated Study Completion Date: | August 2014 |
| Estimated Primary Completion Date: | August 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Lofexidine and Dronabinol
Maintained at 1.8mg/day Lofex. and 60 mg/day of Dronabinol
|
Drug: Lofexidine and Dronabinol
Lofex: .6 mg/ TID Dronabinol: 20 mg/TID
Other Name: Marinol
|
|
Placebo Comparator: Placebo
Lofex. matched placebo Dronabinol placebo
|
Drug: Placebo
Placebo control
Other Name: Placebo
|
Detailed Description:
Cannabis use disorders remain the most common illicit drug use disorder and options for treatment remain limited. Compared to other abusable substances, there has been little investigation of pharmacotherapies for cannabis dependence and no effective pharmacotherapy for cannabis dependence has yet to been developed. The development of effective cannabis dependence pharmacotherapy is an important unmet public health need. Agonist pharmacotherapy strategies have been effective for other substance use disorders (e.g., opioid and nicotine use disorders) and the endocannabinoid system represents a promising target for agonist pharmacotherapy with dronabinol. Lofexidine, a noradrenergic system suppressant, is effective in treating opioid withdrawal and shows promise as a cannabis use disorder pharmacotherapy. Haney et al. (2008) found that the combination of lofexidine and dronabinol (Lofex-Dro) was superior to placebo, lofexidine alone, or dronabinol alone in improving sleep and other cannabis withdrawal symptoms. Further, reduction in craving and relapse was greater for this combined pharmacotherapy relative to either medication alone or placebo. The proposed protocol is a 2 group, double blind, placebo-controlled outpatient study of the safety and efficacy of the combination of dronabinol and lofexidine for the treatment of cannabis dependence. We plan to enroll 180 subjects in a 12-week trial. The primary hypothesis is that dronabinol will act as an agonist treatment while lofexidine will suppress craving- and cue-induced related stress such that the combination will act in a complementary manner to induce prolonged abstinence from marijuana.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Men and women between the ages of 18-60 who meet DSM-IV criteria for current marijuana dependence
- Individuals must report using marijuana at least 5 days a week and have a positive urine test for THC on the day of study entry.
- Individual must describe marijuana as their primary drug of abuse.
- Individuals must be capable of giving informed consent and capable of complying with study procedures.
Exclusion Criteria:
- Meets DSM-IV-TR criteria for schizophrenia, schizoaffective illness, psychotic disorder other than transient psychosis due to drug abuse, major depression, bipolar illness or psychiatric disorders (other than substance abuse) which require psychiatric intervention.
- Individuals who are medically unstable based on laboratory tests, electrocardiogram, medical history, physical examination that would make participation hazardous
- Individuals with liver enzyme function tests greater than three times normal
- Individuals with a history of seizure disorder
- Individuals with current suicidal risk.
- Individuals who are cognitively impaired
- Bradycardia (< 50 beats/minute), hypotension (sitting or standing BP < 90/50), or symptoms attributable to low BP (i.e. lightheadedness or dizziness on standing).
- Nursing mothers and pregnant women. Women of child bearing age will be included in the study provided that they are not pregnant, based on the results of a blood pregnancy test drawn at the time of screening. They must also agree to use a method of contraception with proven efficacy and agree not to become pregnant during the study. To confirm this, urine pregnancy tests will be repeated monthly. Women will be provided a full explanation of the potential dangers of pregnancy while on the study medication. If a woman becomes pregnant, the study medication will be discontinued.
- Individuals who are physiologically dependent on any other drugs (excluding nicotine) that would require a medical intervention
- Individuals with known sensitivity to dronabinol or lofexidine
- Individuals with coronary vascular disease as indicated by history or suspected by abnormal ECG or history of cardiac symptoms
- Individuals currently being treated with an alpha-2 agonist antihypertensive medication
- Individuals currently being prescribed a psychotropic medication (including sleep medication). However, medication for depression is allowed if stable for at least 1 month.
- Individuals who have a job that even mild intoxication would be hazardous (e.g., firefighter, bus driver)
- Individuals who are court-mandated to treatment.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01020019
| Contact: Amy Mahony, MA | (212) 740-7350 | mahonya@pi.cpmc.columbia.edu | |
| Contact: Daniel J Brooks, MA | (212) 740-3205 | brooksd@pi.cpmc.columbia.edu |
| United States, New York | |
| New York State Psychiatric Institute | Recruiting |
| New York, New York, United States, 10032 | |
| Contact: Amy Mahony, M.A. 212-923-3031 mahonya@pi.cpmc.columbia.edu | |
| Contact: Elizabeth Martinez (212) 923-3031 martinez@pi.cpmc.columbia.edu | |
| Principal Investigator: Frances R Levin, M.D. | |
| Principal Investigator: | Frances R Levin, M.D. | Columbia University |
More Information
No publications provided
| Responsible Party: | New York State Psychiatric Institute |
| ClinicalTrials.gov Identifier: | NCT01020019 History of Changes |
| Other Study ID Numbers: | #6015, P50DA009236-16, DPMC |
| Study First Received: | November 24, 2009 |
| Last Updated: | April 9, 2014 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by New York State Psychiatric Institute:
|
Cannabis Dependence Marijuana Dependence Marinol Lofexidine |
Additional relevant MeSH terms:
|
Marijuana Abuse Chemically-Induced Disorders Mental Disorders Substance-Related Disorders Dronabinol Lofexidine Adrenergic Agents Adrenergic Agonists Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Analgesics Analgesics, Non-Narcotic Antihypertensive Agents Cannabinoid Receptor Agonists Cannabinoid Receptor Modulators |
Cardiovascular Agents Central Nervous System Agents Hallucinogens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Molecular Mechanisms of Pharmacological Action Narcotic Antagonists Neurotransmitter Agents Peripheral Nervous System Agents Pharmacologic Actions Physiological Effects of Drugs Psychotropic Drugs Sensory System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on February 27, 2015